News
September 16, 2025
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025
SAN FRANCISCO and SUZHOU, China, Sept. 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major...
Innovent Biologics, a leading global biopharmaceutical company, announced today that it will present a diverse array of research and development findings from its general biomedicine pipeline at the prestigious 34th European Academy of Dermatology and Venereology (EADV) Congress in 2025. The presentation promises to showcase the company's commitment to developing innovative therapies for a broad spectrum of diseases.
The EADV Congress, a significant event in the dermatology and venereology field, provides a crucial platform for Innovent to share its latest advancements with the global scientific community. The company's pipeline spans several therapeutic areas, including oncology, autoimmune disorders, cardiovascular and metabolic diseases, and ophthalmology, demonstrating its dedication to addressing unmet medical needs across diverse patient populations.
While specific details regarding the data to be presented remain under wraps, the announcement signals Innovent's continued momentum in advancing its research programs. The company, known for its focus on developing, manufacturing, and commercializing high-quality medicines, is expected to unveil compelling data that could potentially impact the treatment landscape for various conditions.
Innovent's participation in the EADV Congress underscores its strategic approach to global collaboration and scientific exchange. By presenting its R&D results at this prominent international forum, the company aims to engage with leading experts, foster dialogue, and explore potential partnerships to further accelerate the development and delivery of its innovative therapies to patients worldwide.
The biopharmaceutical firm, listed on the Hong Kong Stock Exchange (HKEX: 01801), has established itself as a key player in the industry. Its presence at the 34th EADV Congress is highly anticipated, as researchers and clinicians eagerly await the opportunity to learn more about Innovent's latest breakthroughs in general biomedicine. The presentations are expected to cover pre-clinical and clinical data, highlighting the efficacy and safety profiles of Innovent's investigational drugs. More detailed information about the specific presentations, including titles and schedules, will likely be released closer to the event date.
The EADV Congress, a significant event in the dermatology and venereology field, provides a crucial platform for Innovent to share its latest advancements with the global scientific community. The company's pipeline spans several therapeutic areas, including oncology, autoimmune disorders, cardiovascular and metabolic diseases, and ophthalmology, demonstrating its dedication to addressing unmet medical needs across diverse patient populations.
While specific details regarding the data to be presented remain under wraps, the announcement signals Innovent's continued momentum in advancing its research programs. The company, known for its focus on developing, manufacturing, and commercializing high-quality medicines, is expected to unveil compelling data that could potentially impact the treatment landscape for various conditions.
Innovent's participation in the EADV Congress underscores its strategic approach to global collaboration and scientific exchange. By presenting its R&D results at this prominent international forum, the company aims to engage with leading experts, foster dialogue, and explore potential partnerships to further accelerate the development and delivery of its innovative therapies to patients worldwide.
The biopharmaceutical firm, listed on the Hong Kong Stock Exchange (HKEX: 01801), has established itself as a key player in the industry. Its presence at the 34th EADV Congress is highly anticipated, as researchers and clinicians eagerly await the opportunity to learn more about Innovent's latest breakthroughs in general biomedicine. The presentations are expected to cover pre-clinical and clinical data, highlighting the efficacy and safety profiles of Innovent's investigational drugs. More detailed information about the specific presentations, including titles and schedules, will likely be released closer to the event date.
Category:
Politics